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Convalescent plasma to treat critically ill
patients with COVID-19: framing the need
for randomised clinical trials
Manu Shankar-Hari1,2* , Lise Estcourt3,4, Heli Harvala5,6, David Roberts3,4, David K. Menon7, On behalf of the
United Kingdom SARS-CoV-2 Convalescent Plasma Evaluation (SCoPE) Consortium
We are in a severe acute respiratory distress syndrome
coronavirus 2 (SARS-CoV-2) pandemic, causing corona-
virus disease (COVID-19). SARS-CoV-2 is an enveloped
RNA virus with cell entry facilitated by spike (S) protein
that has a cleavage site at the S1–S2 boundary and other
structural proteins such as membrane (M), envelope (E),
and nucleocapsid (N) proteins [1]. Currently, there are
two lineages of SARS-CoV-2 virus infecting humans,
with similar virulence and clinical outcomes, derived
from a common ancestor that originated in December
2019 in Wuhan [1, 2]. Most patients who recover from
SARS-CoV-2 illness will develop antibodies and memory
lymphocytes against these proteins, which gives them
immunity [3]. In this editorial, we discuss the biological,
operational, and methodological questions that arise
when designing a randomised controlled trial (RCT) of
convalescent plasma in COVID-19.
What is convalescent plasma therapy?
Convalescent plasma refers to acellular plasma fraction
of blood, containing antibodies against SARS-CoV-2 anti-
gens, with virus neutralisation properties, collected from
patients who have recovered from SARS-CoV-2 infections.
Passive immunisation with ABO blood group-compatible
convalescent plasma will reduce viral burden as neutralising
antibodies will binding to the viral spike protein to either
prevent interaction with angiotensin-converting enzyme-2
receptor or block the conformational changes in spike
protein preventing fusion to host cell membrane and
provide immunomodulation.
What do we know thus far about convalescent
plasma therapy in COVID-19 illness?
Since the recent Cochrane review that highlighted very
low-certainty evidence on the effectiveness and safety of
convalescent plasma in COVID-19 patients [4], Joy-
ner and colleagues have reported safety results from a
compassionate use convalescent plasma therapy
programme in 5000 adults with COVID-19. They high-
light that convalescent plasma is a safe treatment with
an overall serious adverse event rate of < 1% (n =
36 events), with TACO occuring in 7 patients, TRALI in
11 patients, and allergic transfusion reaction in 3 pa-
tients [5]. To date, one RCT has been published. This
open-label trial stopped early after recruiting 103 of a
planned 200 patients sample size were enrolled. The
stoppage was due to low patient recruitment, as the pan-
demic abated in China, and importantly not for safety
reasons [6]. The participants had either severe (respira-
tory distress and/or hypoxemia) or life-threatening
(shock, organ failure, or requiring mechanical ventila-
tion) COVID-19 illness. The intervention, ABO-
compatible convalescent plasma at a dose of 4 to 13ml/
kg of recipient body weight, and with an S-RBD-specific
IgG titre of at least 1:640. The primary outcome was
time to clinical improvement within 28 days, defined as
patient discharged alive or reduction of 2 points on a 6-
point disease severity scale. The overall trial result was
no statistically significant improvement in time to clin-
ical improvement within 28 days between convalescent
plasma with standard of care versus standard of
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care alone. However, any inference from this trial is lim-
ited by it's early termination.
Why do we need more RCTs of convalescent
plasma?
The risks of administering plasma screened for common
blood-borne pathogens are small, but include allergy/
anaphylaxis, transfusion-related acute lung injury (TRALI),
and transfusion-associated circulatory overload (TACO)
[7]. TRALI and TACO are relevant as many COVID-19
patients have incipient respiratory failure that may worsen
with convalescent plasma transfusion-related volume load-
ing. Another specific concern with this intervention is anti-
body-dependent enhancement (ADE). In SARS-1
coronaviruses, ADE occurs by S protein neutralising
antibodies enhancing viral entry into cells though
fragment-crystallisable (Fc) receptor expressing cells
such as monocytes [8]. This has been shown to worsen
lung injury in SARS-1 patients [9]. Non-randomised
clinical use (compassionate) will not provide evidence
of efficacy, which is an important consideration, as pas-
sive immunotherapy was ineffective in severe influenza
A [10], and Ebola [11]. The impact of these harms
would be difficult to identify outside a well-conducted
RCT that collects adverse event data in a standardised
way, whilst answering the efficacy question.
Can we rapidly provide convalescent plasma with
neutralising antibodies during a pandemic?
Convalescent plasma can be collected safely from indi-
viduals who have recovered from laboratory-confirmed
SARS-CoV-2 infection, as neutralising antibody re-
sponses begin by 14 days and continue to increase over
the next few weeks. Currently, it is uncertain how long
these antibodies persist, but in other coronavirus infec-
tions, neutralising antibodies may persist at high titres
for at least 3 months before declining [12]. Therefore,
collection of plasma around 28 days after recovery will
provide an effective product with high titres of neutralis-
ing antibodies.
However, neither the method to assess viral neutralisa-
tion ability of convalescent plasma prior to administra-
tion nor the minimum titre of neutralising antibody that
is required for treating critically ill patients with
COVID-19 is known. There are two methods to assess
viral neutralisation ability—pseudotype and live-virus
assays. Pseudotype assays using harmless viruses that ex-
press the coronavirus spike protein, the target of neutra-
lising antibodies, are a safer, easier, and more sensitive
method for detecting neutralising antibody than live-
virus assays that assess neutralisation of invasion of tis-
sue culture cells by live virus [13]. The titres of antibody
dose vary between studies, from 400 ml of ABO-
compatible convalescent plasma with neutralising
antibody titre > 1:40 [14] to single 200 ml dose of inacti-
vated convalescent plasma with neutralising antibody
titre > 1:640 [15].
What are the key design issues to consider in
RCTs of convalescent plasma?
Current trials include participants with a range of
COVID-19 illness spectrum, the intervention (convales-
cent plasma different timing, different doses, and need
for molecular evidence of viral infection) and compara-
tors are different, ranging from standard of care to use
of regular plasma for blinding that adds transfusion-
related risks in comparator population, and outcomes
differ between trials. It is conceivable that the treatment
effect of convalescent plasma may differ by illness sever-
ity, by dose in terms of volume, concentration of neu-
tralisation antibody, and the risk of ADE along with
other adverse events during COVID-19 illness (Table 1)
[4].
In summary, there is a clear biological framework for
considering convalescent plasma as a potential interven-
tion in COVID-19 illness. However, we need high-quality
randomised controlled trials prior to using convalescent
plasma as standard care in SARS-CoV-2 infections.
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